MASP2 and non-small cell lung carcinoma: Later, Chen et al. [47] reported significantly higher concentrations of MASP-2 in sera from patients diagnosed with non-small cell lung cancers compared with those with benign tumours or healthy controls; they suggested MASP-2 (in combination with isocitrate dehydrogenase 1 (IDH1) and the cytokeratin 19 fragment, Cyfra21-1) could serve as a disease marker.